This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Durata Therapeutics, Inc.
Durata Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2012, the company has rapidly established itself as a leader in developing innovative therapies for infectious diseases, particularly focusing on antibiotic resistance. With a commitment to addressing unmet medical needs, Durata has achieved significant milestones, including the successful launch of its flagship product, Dalvance (dalbavancin), which offers a unique, long-acting treatment option for skin infections. Operating primarily in the US and expanding its reach globally, Durata Therapeutics is recognised for its dedication to research and development, positioning itself at the forefront of the fight against resistant pathogens. The company’s strategic focus on high-quality, effective treatments has garnered notable achievements, solidifying its reputation within the healthcare community.
DitchCarbon Score
How does Durata Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Durata Therapeutics, Inc.'s score of 65 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Durata Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. As part of its corporate family relationship with AbbVie Inc., Durata Therapeutics may align with the climate initiatives and targets set by AbbVie. However, specific reduction targets or achievements for Durata Therapeutics are not detailed in the available information. The company does not appear to have its own distinct climate pledge or reduction initiatives listed. For context, AbbVie Inc. has established various climate commitments, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which may influence Durata Therapeutics' climate strategy. Nonetheless, without specific emissions data or reduction targets from Durata Therapeutics itself, a comprehensive overview of its carbon emissions and climate commitments remains unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Durata Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
